AbbVie Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 AbbVie Inc 公司

公司简介

公司代码ABBV

公司名称AbbVie Inc

上市日期Jan 02, 2013

成立日期2012

CEOMr. Robert A. Michael, CPA

员工数量55000

证券类型Ordinary Share

年结日Jan 02

公司地址1 N Waukegan Rd

城市NORTH CHICAGO

上市交易所NYSE Consolidated

国家United States of America

邮编60064

电话18479327900

网址https://www.abbvie.com/

公司代码ABBV

上市日期Jan 02, 2013

成立日期2012

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Richard A. Gonzalez

Executive Chairman of the Board

388.92K

-1.56%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

221.98K

+10.69%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

+1.00%

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

+2.68%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.27K

+16.14%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

+3.27%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

37.25K

+3.68%

Dr. Robert J. Alpern, M.D.

Independent Director

34.44K

+3.99%

Mr. Frederick H. (Rick) Waddell

Independent Director

27.75K

+5.00%

Ms. Melody B. Meyer

Independent Director

15.29K

+9.46%

名称

名称/职务

职务

持股

持股变动

Mr. Richard A. Gonzalez

Executive Chairman of the Board

388.92K

-1.56%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

221.98K

+10.69%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

+1.00%

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

+2.68%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.27K

+16.14%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

+3.27%

收入明细

单位: USD更新时间: 3月5日周三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Immunology-SKYRIZI

11.71B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.59%

Hematologic Oncology-IMBRUVICA

3.34B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.82%

Other

23.02B

40.86%

地区USD

名称

营收

占比

United States

40.78B

72.38%

International

11.50B

20.42%

All other countries

3.03B

5.38%

Germany

1.46B

2.60%

Japan

1.12B

1.99%

Other

-1.57B

-2.78%

业务

地区

业务USD

名称

营收

占比

Immunology-SKYRIZI

11.71B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.59%

Hematologic Oncology-IMBRUVICA

3.34B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.82%

Other

23.02B

40.86%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.76%

BlackRock Institutional Trust Company, N.A.

5.10%

State Street Global Advisors (US)

4.51%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.59%

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.76%

BlackRock Institutional Trust Company, N.A.

5.10%

State Street Global Advisors (US)

4.51%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.59%

股东类型

股东统计

占比

Investment Advisor

34.04%

Investment Advisor/Hedge Fund

29.85%

Research Firm

2.78%

Bank and Trust

2.23%

Pension Fund

2.22%

Sovereign Wealth Fund

1.52%

Insurance Company

0.63%

Hedge Fund

0.52%

Holding Company

0.39%

Other

25.79%

机构持股

更新时间: 2月20日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q1

5107

1.31B

74.41%

+8.05M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.29B

73.54%

-7.43M

2024Q2

4916

1.29B

73.53%

+2.26M

2024Q1

4930

1.28B

72.58%

-1.46M

2023Q4

4882

1.27B

72.31%

-1.48M

2023Q3

4694

1.26B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.41M

2023Q1

4658

1.26B

71.97%

-18.58M

2022Q4

4628

1.26B

71.69%

-10.54M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

172.30M

9.76%

+1.44M

+0.84%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

90.08M

5.1%

+893.97K

+1.00%

Dec 31, 2024

State Street Global Advisors (US)

79.62M

4.51%

+553.55K

+0.70%

Dec 31, 2024

Geode Capital Management, L.L.C.

37.14M

2.1%

+983.88K

+2.72%

Dec 31, 2024

Capital Research Global Investors

33.98M

1.92%

+778.12K

+2.34%

Dec 31, 2024

JP Morgan Asset Management

33.90M

1.92%

+881.82K

+2.67%

Dec 31, 2024

Capital International Investors

28.53M

1.61%

-8.25M

-22.43%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

27.43M

1.55%

+3.59M

+15.09%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

25.09M

1.42%

+2.61M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.68M

1.28%

+844.34K

+3.86%

Dec 31, 2024

持股ETF

更新时间: 3月5日周三

机构名称

占比

First Trust Morningstar Dividend Leaders Index Fund

8.4%

Federated Hermes MDT Large Cap Value ETF

6.7%

Health Care Select Sector SPDR Fund

6.52%

First Trust NASDAQ Pharmaceuticals ETF

6.38%

VanEck Pharmaceutical ETF

6.3%

Proshares Ultra Health Care

5.89%

iShares U.S. Healthcare ETF

5.69%

Goldman Sachs Future Health Care Equity ETF

5.19%

Fidelity MSCI Health Care Index ETF

5.12%

Direxion Daily Healthcare Bull 3X Shares

5.09%

First Trust Morningstar Dividend Leaders Index Fund

占比8.4%

Federated Hermes MDT Large Cap Value ETF

占比6.7%

Health Care Select Sector SPDR Fund

占比6.52%

First Trust NASDAQ Pharmaceuticals ETF

占比6.38%

VanEck Pharmaceutical ETF

占比6.3%

Proshares Ultra Health Care

占比5.89%

iShares U.S. Healthcare ETF

占比5.69%

Goldman Sachs Future Health Care Equity ETF

占比5.19%

Fidelity MSCI Health Care Index ETF

占比5.12%

Direxion Daily Healthcare Bull 3X Shares

占比5.09%

分红派息

近5年累计派现 48.58B 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

AbbVie Inc

211.540USD

AbbVie Inc

211.540

概览

公司